Xu, X., Duan, S., Hua, X., Li, Z., He, R., & Zhang, Z. (2022). Stable inheritance of H3.3-containing nucleosomes during mitotic cell divisions. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-30298-4

Bercow, A. S., Rauh-Hain, J. A., Melamed, A., Mazina, V., Growdon, W. B., del Carmen, M. G., Goodman, A., Bouberhan, S., Bregar, A., Eisenhauer, E. L., Molina, G., & Minami, C. (2022). Guideline-Discordant Care in Early-Stage Vulvar Cancer. Obstetrics & Gynecology, 140(6), 1031–1041. https://doi.org/10.1097/aog.0000000000004992

Yang, K., Cao, Y., Gurjao, C., Liu, Y., Guo, C.-G., Lo, C.-H., Zong, X., Drew, D., Geraghty, C., Prezioso, E., Moore, M., Williams, C., Riley, T., Saul, M., Ogino, S., Giannakis, M., Bass, A., Schoen, R. E., & Chan, A. T. (2022). Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective Cohorts. Gastroenterology, 163(6), 1522-1530.e5. https://doi.org/10.1053/j.gastro.2022.08.020

Pfledderer, C. D., Gren, L. H., Frost, C. J., Andrulis, I. L., Chung, W. K., Genkinger, J., Glendon, G., Hopper, J. L., John, E. M., Southey, M., Terry, M. B., & Daly, M. B. (2022). Women’s thoughts on receiving and sharing genetic information: Considerations for genetic counseling. Journal of Genetic Counseling, 31(6), 1249–1260. Portico. https://doi.org/10.1002/jgc4.1599

Mo, Y., Duan, S., Zhang, X., Hua, X., Zhou, H., Wei, H.-J., Watanabe, J., McQuillan, N., Su, Z., Gu, W., Wu, C.-C., Vakoc, C. R., Hashizume, R., Chang, K., & Zhang, Z. (2022). Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4. Cancer Discovery, 12(12), 2906–2929. https://doi.org/10.1158/2159-8290.cd-21-1492

Kim, M., Singh, M., Lee, B.-K., Hibbs, M., Richardson, K., Ellies, L., Wintle, L., Stuart, L. M., Wang, J. Y., Voon, D. C., Blancafort, P., Wang, J., Kim, J., Leedman, P. J., & Woo, A. J. (2022). A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer. Oncogenesis, 11(1). https://doi.org/10.1038/s41389-022-00435-1

Laise, P., Stanifer, M. L., Bosker, G., Sun, X., Triana, S., Doldan, P., La Manna, F., De Menna, M., Realubit, R. B., Pampou, S., Karan, C., Alexandrov, T., Kruithof-de Julio, M., Califano, A., Boulant, S., & Alvarez, M. J. (2022). A model for network-based identification and pharmacological targeting of aberrant, replication-permissive transcriptional programs induced by viral infection. Communications Biology, 5(1). https://doi.org/10.1038/s42003-022-03663-8

Kehm, R. D., Walter, E. J., Oskar, S., White, M. L., Tehranifar, P., Herbstman, J. B., Perera, F., Lilge, L., Miller, R. L., & Terry, M. B. (2022). Exposure to polycyclic aromatic hydrocarbons during pregnancy and breast tissue composition in adolescent daughters and their mothers: a prospective cohort study. Breast Cancer Research, 24(1). https://doi.org/10.1186/s13058-022-01546-8

Liu, H., Forouhar, F., Lin, A. J., Wang, Q., Polychronidou, V., Soni, R. K., Xia, X., & Stockwell, B. R. (2022). Small-molecule allosteric inhibitors of GPX4. Cell Chemical Biology, 29(12), 1680-1693.e9. https://doi.org/10.1016/j.chembiol.2022.11.003

Beauchemin, M., Santacroce, S. J., Bona, K., Dang, H., Alexander, S., Allen, K., De Los Santos, C., Fisher, B., Muñeton-Castaño, Y., Ponce, O., Vargas, S., Sugalski, A., Sung, L., & Parsons, S. (2022). Rationale and design of Children’s Oncology Group (COG) study ACCL20N1CD: financial distress during treatment of acute lymphoblastic leukemia in the United States. BMC Health Services Research, 22(1). https://doi.org/10.1186/s12913-022-08201-0

Moodley, Y., Govender, K., van Wyk, J., Reddy, S., Ning, Y., Wexner, S., Stopforth, L., Bhadree, S., Naidoo, V., Kader, S., Cheddie, S., Neugut, A. I., & Kiran, R. P. (2022). Predictors of treatment refusal in patients with colorectal cancer: A systematic review. Seminars in Oncology, 49(6), 456–464. https://doi.org/10.1053/j.seminoncol.2023.01.002

Ilozumba, M. N., Yao, S., Llanos, A. A. M., Omilian, A. R., Zhang, W., Datta, S., Hong, C.-C., Davis, W., Khoury, T., Bandera, E. V., Higgins, M., Ambrosone, C. B., & Cheng, T.-Y. D. (2022). mTOR pathway gene expression in association with race and clinicopathological characteristics in Black and White breast cancer patients. Discover Oncology, 13(1). https://doi.org/10.1007/s12672-022-00497-y

Wu, H.-C., Kehm, R., Santella, R. M., Brenner, D. J., & Terry, M. B. (2022). DNA repair phenotype and cancer risk: a systematic review and meta-analysis of 55 case–control studies. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-07256-7

Lima, S. M., Nazareth, M., Schmitt, K. M., Reyes, A., Fleck, E., Schwartz, G. K., Terry, M. B., & Hillyer, G. C. (2022). Interest in genetic testing and risk-reducing behavioral changes: results from a community health assessment in New York City. Journal of Community Genetics, 13(6), 605–617. https://doi.org/10.1007/s12687-022-00610-2

Stillman, M. D., Kusche, N., Toledano, S., Hilfrank, K. J., Yoon, C., Gabre, J. T., Rustgi, S. D., Hur, C., Kastrinos, F., Ryeom, S. W., & Yoon, S. S. (2022). Short and long‐term outcomes of prophylactic total gastrectomy in 54 consecutive individuals with germline pathogenic mutations in the CDH1 gene. Journal of Surgical Oncology, 126(8), 1413–1422. Portico. https://doi.org/10.1002/jso.27084

Anderson, C. B., Chen, L., Chang, S. S., McKiernan, J. M., & Wright, J. (2022). Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG. Clinical Genitourinary Cancer, 20(6), 595–603. https://doi.org/10.1016/j.clgc.2022.07.001

Baik, J. E., Li, L., Shah, M. A., Freedberg, D. E., Jin, Z., Wang, T. C., & Han, Y. W. (2022). Circulating IgA Antibodies AgainstFusobacterium nucleatumAmyloid Adhesin FadA are a Potential Biomarker for Colorectal Neoplasia. Cancer Research Communications, 2(11), 1497–1503. https://doi.org/10.1158/2767-9764.crc-22-0248

Gurbatri, C. R., Arpaia, N., & Danino, T. (2022). Engineering bacteria as interactive cancer therapies. Science, 378(6622), 858–864. https://doi.org/10.1126/science.add9667

Deb, D., Zhu, S., LeBlanc, M. J., & Danino, T. (2022). Assessing chemotherapy dosing strategies in a spatial cell culture model. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.980770

de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., Morin, R. D., Nadel, B., Pileri, S. A., Rosenquist, R., Rossi, D., Salaverria, I., Steidl, C., Treon, S. P., Zelenetz, A. D., … Scott, D. W. (2022). Genomic profiling for clinical decision making in lymphoid neoplasms. Blood, 140(21), 2193–2227. https://doi.org/10.1182/blood.2022015854

Li, D., Yang, J., Malik, V., Huang, Y., Huang, X., Zhou, H., & Wang, J. (2022). An RNAi screen of RNA helicases identifies eIF4A3 as a regulator of embryonic stem cell identity. Nucleic Acids Research, 50(21), 12462–12479. https://doi.org/10.1093/nar/gkac1084

Zeidan, A. M., Platzbecker, U., Garcia-Manero, G., Sekeres, M. A., Fenaux, P., DeZern, A. E., Greenberg, P. L., Savona, M. R., Jurcic, J. G., Verma, A. K., Mufti, G. J., Buckstein, R., Santini, V., Shetty, J. K., Ito, R., Zhang, J., Zhang, G., Ha, X., Backstrom, J. T., & Komrokji, R. S. (2022). Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood, 140(20), 2170–2174. https://doi.org/10.1182/blood.2022016171

Galeano Niño, J. L., Wu, H., LaCourse, K. D., Kempchinsky, A. G., Baryiames, A., Barber, B., Futran, N., Houlton, J., Sather, C., Sicinska, E., Taylor, A., Minot, S. S., Johnston, C. D., & Bullman, S. (2022). Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature, 611(7937), 810–817. https://doi.org/10.1038/s41586-022-05435-0

DeAngelo, D. J., Pullarkat, V. A., Piris-Villaespesa, M., George, T. I., Patel, J. L., Ustun, C., Bose, P., Heaney, M. L., Sachs, J., Sun, L., Pilla, A., Exter, B., Jolin, H. A., & Tashi, T. (2022). Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM). Blood, 140(Supplement 1), 1512–1513. https://doi.org/10.1182/blood-2022-156311

Davids, M. S., Sharman, J. P., Eyre, T. A., Woyach, J. A., de Miranda, P. A. P., Shahkarami, M., Butturini, A., Emeribe, U., & Byrd, J. C. (2022). Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features. Blood, 140(Supplement 1), 4173–4175. https://doi.org/10.1182/blood-2022-157018

Mosialou, I., Ali, A. M., Adams, R., Corper, A., Woods, C. M., Fan, X., Raza, A., & Kousteni, S. (2022). Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance. Blood, 140(Supplement 1), 2902–2902. https://doi.org/10.1182/blood-2022-167042

Wang, M. L., Shah, N. N., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I. W., Tessoulin, B., Alencar, A. J., Ma, S., Lech-Marańda, E., Rhodes, J. M., Patel, K., Woyach, J. A., Lamanna, N., … Mato, A. R. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 9368–9372. https://doi.org/10.1182/blood-2022-159425

Byrd, J. C., Woyach, J. A., Furman, R. R., Martin, P., O’Brien, S., Brown, J. R., Stephens, D. M., Barrientos, J. C., Patten, P. E., Munir, T., Patel, K., Butturini, A., de Borja, M., Wang, M. H., Jain, N., & Wierda, W. G. (2022). Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up. Blood, 140(Supplement 1), 9865–9867. https://doi.org/10.1182/blood-2022-159542

Zhang, C., Tremblay, D., Magnotti, J., Ronner, L., Podoltsev, N. A., Gotlib, J., Heaney, M. L., Kuykendall, A., O’Connell, C. L., Fleischman, A. G., Mesa, R., Yacoub, A., Mascarenhas, J., & Shammo, J. M. (2022). Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis. Blood, 140(Supplement 1), 9693–9695. https://doi.org/10.1182/blood-2022-157873

Blachly, J. S., Stephens, D. M., Ye, J. C., Lamanna, N., Jain, N., Niesman, M., Zhang, K., & Woyach, J. A. (2022). Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL. Blood, 140(Supplement 1), 2324–2325. https://doi.org/10.1182/blood-2022-171203

Estrella, B., Pazos, M. A., Ricker, E. C., Ryu, Y. K., Piorczynski, T. B., Liu, Y., Tolu, S., & Amengual, J. E. (2022). First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade. Blood, 140(Supplement 1), 358–359. https://doi.org/10.1182/blood-2022-166929

Lee, H. J., Choi, M. Y., Siddiqi, T., Rhodes, J. M., Wierda, W. G., Isufi, I., Tuscano, J. M., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, M., Jamieson, C., & Kipps, T. J. (2022). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood, 140(Supplement 1), 566–568. https://doi.org/10.1182/blood-2022-167153

Esplin, I., Huang, Y., Bhat, S. A., Grantier, C., Grever, M. R., Hoffman, C., Kittai, A. S., Lucas, M. S., Moran, M. E., Reid, M., Suresh, S., Woyach, J. A., & Rogers, K. A. (2022). Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study. Blood, 140(Supplement 1), 4166–4168. https://doi.org/10.1182/blood-2022-167314

Di Meo, F., Iyer, A., Akama, K., Yu, C., Cheng, R., Cesarano, A., Marino, S., Aljoufi, A., Soni, R., Roda, J. M., Sissons, J., Vu, L. P., Guzman, M. L., Huang, K., Roodman, D. G., & Perna, F. (2022). A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma. Blood, 140(Supplement 1), 671–672. https://doi.org/10.1182/blood-2022-167584

Wierda, W. G., Lewis, D. J., Ghia, P., Shah, N. N., Coombs, C. C., Cheah, C. Y., Lamanna, N., Rhodes, J. M., Hoffmann, M., Ma, S., Eyre, T. A., Munir, T., Patel, M. R., Alencar, A. J., Tam, C. S., Seymour, J. F., Jurczak, W., Lech-Marańda, E., Roeker, L. E., … Mato, A. R. (2022). Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 846–849. https://doi.org/10.1182/blood-2022-157058

Orlando, E., Ford, M., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation. Blood, 140(Supplement 1), 12085–12086. https://doi.org/10.1182/blood-2022-158050

Ford, M., Orlando, E., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 3794–3795. https://doi.org/10.1182/blood-2022-163813

Shah, N. N., Wang, M. L., Brown, J. R., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Gastinne, T., Ghia, P., Lamanna, N., Hoffmann, M., Patel, M. R., Flinn, I. W., Gerson, J. N., Ma, S., Coombs, C. C., … Mato, A. R. (2022). Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 4127–4132. https://doi.org/10.1182/blood-2022-159035

Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Marańda, E., Lamanna, N., Tam, C. S., Seymour, J. F., Shah, N. N., Coombs, C. C., Ujjani, C. S., Patel, M. R., Fakhri, B., Cheah, C. Y., Alencar, A. J., Cohen, J. B., … Jurczak, W. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 2316–2320. https://doi.org/10.1182/blood-2022-159497

Ford, M., Orlando, E., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 3777–3778. https://doi.org/10.1182/blood-2022-160147

Frangoul, H., Locatelli, F., Bhatia, M., Mapara, M. Y., Molinari, L., Sharma, A., Lobitz, S., de Montalembert, M., Rondelli, D., Steinberg, M., Walters, M. C., Imren, S., Zhang, L., Sharma, A., Song, Y., Simard, C., Hobbs, W., & Grupp, S. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Blood, 140(Supplement 1), 29–31. https://doi.org/10.1182/blood-2022-162353

Lim, E. A., Bendell, J. C., Falchook, G. S., Bauer, T. M., Drake, C. G., Choe, J. H., George, D. J., Karlix, J. L., Ulahannan, S., Sachsenmeier, K. F., Russell, D. L., Moorthy, G., Sidders, B. S., Pilling, E. A., Chen, H., Hattersley, M. M., Das, M., Kumar, R., Pouliot, G. P., & Patel, M. R. (2022). Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research, 28(22), 4871–4884. https://doi.org/10.1158/1078-0432.ccr-22-0612

Locatelli, F., Lang, P., Li, A., Corbacioglu, S., de la Fuente, J., Wall, D. A., Liem, R., Meisel, R., Mapara, M. Y., Shah, A. J., Cappellini, M. D. D., Kattamis, A., Sheth, S., Bobruff, Y., Bower, L., Zhang, L., Sharma, A., Song, Y., Hobbs, W., & Frangoul, H. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. Blood, 140(Supplement 1), 4899–4901. https://doi.org/10.1182/blood-2022-166881

Seymour, J. F., Byrd, J. C., Munir, T., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O’Brien, S., Brown, J. R., Mato, A. R., Stilgenbauer, S., Fehn, T., de Miranda, P. A. P., Higgins, K., John, E., de Borja, M., Jurczak, W., & Woyach, J. A. (2022). Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 140(Supplement 1), 7050–7052. https://doi.org/10.1182/blood-2022-157060

Oh, S. T., Mesa, R., Harrison, C., Bose, P., Gerds, A. T., Heaney, M. L., Gupta, V., Scott, B. L., Kiladjian, J.-J., Lucchesi, A., Buckley, S., Tyavanagimatt, S., Roman-Torres, K., Mascarenhas, J., & Verstovsek, S. (2022). Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis. Blood, 140(Supplement 1), 1518–1521. https://doi.org/10.1182/blood-2022-156936

Xu, X., Hua, X., Brown, K., Ren, X., & Zhang, Z. (2022). Mcm2 promotes stem cell differentiation via its ability to bind H3-H4. ELife, 11. CLOCKSS. https://doi.org/10.7554/elife.80917

Ye, S., Liu, Y., Zhang, T., Feng, H., Liu, Y., & Ma, L. (2022). Analysis of the correlation between non-alcoholic fatty liver disease and the risk of colorectal neoplasms. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1068432

Van Egeren, D., Kohli, K., Warner, J. L., Bedard, P. L., Riely, G., Lepisto, E., Schrag, D., LeNoue-Newton, M., Catalano, P., Kehl, K. L., Michor, F., Fiandalo, M., Foti, M., Khotskaya, Y., Lee, J., Peters, N., Sweeney, S., Abraham, J., … Walther, Z. (2022). Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-21448-1

Conte, M. I., Poli, M. C., Taglialatela, A., Leuzzi, G., Chinn, I. K., Salinas, S. A., Rey-Jurado, E., Olivares, N., Veramendi-Espinoza, L., Ciccia, A., Lupski, J. R., Aldave Becerra, J. C., Mace, E. M., & Orange, J. S. (2022). Partial loss-of-function mutations in GINS4 lead to NK cell deficiency with neutropenia. JCI Insight, 7(21). https://doi.org/10.1172/jci.insight.154948

Neugut, A. I. (2022). Cancer as a Disease of the Cell. The Oncologist, 27(11), 901–902. https://doi.org/10.1093/oncolo/oyac152